{"generic":"Japanese Encephalitis Virus Vaccine, Inactivated","drugs":["Japanese Encephalitis Virus Vaccine, Inactivated","Je-Vax"],"mono":{"0":{"id":"929337-s-0","title":"Generic Names","mono":"Japanese Encephalitis Virus Vaccine, Inactivated"},"1":{"id":"929337-s-1","title":"Dosing and Indications","sub":{"0":{"id":"929337-s-1-4","title":"Adult Dosing","mono":"<b>Japanese encephalitis virus disease; Prophylaxis:<\/b> (JE-VAX(R)) reserved for use in children 1 through 16 yr old "},"1":{"id":"929337-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and effectiveness in infants under one year of age have not been established<\/li><li><b>Japanese encephalitis virus disease; Prophylaxis:<\/b> (JE-VAX(R)); over 3 yr old) 1 mL SUBQ x 3 doses on days 0, 7, and 30; booster dose in 2 yr<\/li><li><b>Japanese encephalitis virus disease; Prophylaxis:<\/b> (JE-VAX(R)); 1 to 3 yr old) 0.5 mL SUBQ on days 0, 7, and 30; booster dose in 2 yr<\/li><\/ul>"},"3":{"id":"929337-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Japanese encephalitis virus disease; Prophylaxis<br\/>"}}},"3":{"id":"929337-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929337-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to Japanese encephalitis virus vaccine product (JE-VAX(R))<\/li><li>hypersensitivity to murine-derived products<\/li><li>hypersensitivity to thimerosal<\/li><\/ul>"},{"id":"929337-s-3-10","title":"Precautions","mono":"<ul><li>administer concurrently with other vaccines when possible<\/li><li>adverse reactions manifesting as generalized urticaria or angioedema may occur within minutes following vaccination; most reactions occur within 10 days with the majority occurring within 48 hours<\/li><li>alcohol intake<\/li><li>observe patients for 30 minutes following vaccination; advise patients to remain near access to medical care for 10 days after receiving the vaccine<\/li><li>past history of urticaria after hymenoptera envenomation, drugs, physical or other provocations, or of idiopathic cause;  greater risk of developing reactions to vaccine<\/li><li>pregnancy<\/li><\/ul>"},{"id":"929337-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"929337-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk is minimal.<br\/>"}]},"5":{"id":"929337-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Swelling<\/li><li><b>Dermatologic:<\/b>Erythema, Injection site reaction, Rash<\/li><li><b>Endocrine metabolic:<\/b>Shivering<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain, Nausea, Vomiting<\/li><li><b>Musculoskeletal:<\/b>Myalgia<\/li><li><b>Neurologic:<\/b>Dizziness, Headache<\/li><li><b>Other:<\/b>Fever, Malaise, Tenderness<\/li><\/ul><b>Serious<\/b><ul><li><b>Neurologic:<\/b>Encephalitis, Encephalopathy, Peripheral neuropathy, Seizure<\/li><li><b>Respiratory:<\/b>Respiratory distress (rare)<\/li><li><b>Other:<\/b>Angioedema<\/li><\/ul>"},"6":{"id":"929337-s-6","title":"Drug Name Info","sub":{"0":{"id":"929337-s-6-17","title":"US Trade Names","mono":"Je-Vax<br\/>"},"2":{"id":"929337-s-6-19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"929337-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"929337-s-7","title":"Mechanism Of Action","mono":"Systemic: Following subcutaneous administration, JE vaccine induces the formation of protective neutralizing antibodies.  <br\/>"},"9":{"id":"929337-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>(injection) for SUBQ administration only; do not administer JE-VAX(R) IV or IM<br\/><\/li><li><b>Subcutaneous<\/b><br\/>reconstitute JE-VAX(R) with supplied diluent (Sterile Water for Injection); shake well<br\/><\/li><\/ul>"},"13":{"id":"929337-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patients to remain near access to medical care for 10 days after receiving the vaccine, as most adverse reactions occur within the first 10 days of vaccination.<\/li><li>Tell patient to wait at least 10 days following completion of immunization schedule before traveling to foreign countries.<\/li><li>This drug may cause swelling, erythema, shivering, abdominal pain, nausea, vomiting, myalgia, dizziness, headache, fever, malaise, or tenderness.<\/li><li>Instruct patient to report signs\/symptoms of encephalitis, peripheral neuropathy, seizure, or angioedema (deep swelling around eyes and lips and sometimes hands and feet).<\/li><li>Patients should not drink large amounts of alcohol for 2 days following vaccine administration.<\/li><\/ul>"}}}